Home
October 2008 November 2008 December 2008
Su Mo Tu We Th Fr Sa
Week 44 1
Week 45 2 3 4 5 6 7 8
Week 46 9 10 11 12 13 14 15
Week 47 16 17 18 19 20 21 22
Week 48 23 24 25 26 27 28 29
Week 49 30

Prostate Volume and Pathologic Prostate Cancer Outcomes after Radical Prostatectomy - Abstract Show Comments PDF Print E-mail
  
Monday, 17 December 2007

Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York, USA

To more clearly elucidate the relationship between prostate volume (PV) and prostate cancer parameters.

The Urologic Oncology Database was reviewed. A total of 3460 patients had undergone radical prostatectomy from 1988 to 2006. Of these, 2600 with complete data were included in the study and were stratified by the PV: normal (0 to 40 cm(3)), moderate (40 to 80 cm(3)), or large (greater than 80 cm(3)). The prostate cancer variables were evaluated using analysis of variance. Regression models were used to determine the role of PV in Gleason sum discordance (greater than 1 unit) controlling for prostate-specific antigen level and clinical and pathologic stage.

Of the 2600 patients, 1453 (55.2%) had a normal, 1035 (39.8%) a moderate, and 130 (5.0%) a large PV. Patients with a normal PV were more likely to have a Gleason sum greater than 6 at biopsy (46.2%) and radical retropubic prostatectomy (68.4%) compared with patients with a moderate (39.0% and 58.9%, respectively) or a large (41.5% and 57.7%, respectively) PV (P = 0.005 and P = 0.001, respectively). Patients with a normal PV had greater rates of extraprostatic extension (32.3%) and positive margins (28.2%) compared with those with a moderate (25.5% and 22.4%, respectively) or a large (23.3% and 20.3%, respectively) PV (P = 0.002 and P = 0.005, respectively). Of all 2600 patients, 55.9% had no change between the biopsy and pathologic Gleason sum, 255 (9.8%) were downgraded, and 890 (34.3%) were upgraded. Patients with a large PV had a greater rate of downgrading (16.2%) than those with a normal (8.7%) or moderate (10.5%) PV (P = 0.01). Patients upgraded had the greatest rate of pathologically advanced disease (35.3% with Stage T3 or greater, P <0.001). On multivariate regression analysis, PV (odds ratio 0.99, P = 0.005), prostate-specific antigen level (odds ratio 1.03, P <0.001), and age (odds ratio 1.03, P <0.001) were predictors of Gleason discordance +/-2.

The results of our study have shown that patients with a large PV (greater than 80 cm(3)) are more likely to have a lower Gleason sum, locally confined and less-aggressive pathologic disease, and were more often downgraded.

Written by
Pierorazio PM, Kinnaman MD, Wosnitzer MS, Benson MC, McKiernan JM, Goluboff ET.

Reference
Urology. 2007 Oct;70(4):696-701
doi:10.1016/j.urology.2007.05.022

PubMed Abstract
PMID:17991540

UroToday.com Prostate Cancer Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >